Skip to main content
STEK
OTC Trade & Services

Stemtech Corp Reports 43% Revenue Decline, Widening Losses, Going Concern Warning, and Massive Dilution

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$0
Mkt Cap
$46.395K
52W Low
$0
52W High
$0.042
Market data snapshot near publication time

Summary

Stemtech Corp's annual report highlights severe financial challenges, including a 43% revenue drop, widening losses, a going concern warning, and massive shareholder dilution from debt conversions.


Key Events

  • Going Concern Warning Issued

    Management and the auditor express substantial doubt about the company's ability to continue as a going concern, citing recurring losses, negative cash flows, an accumulated deficit of $34.9 million, and a working capital deficiency of $10.4 million as of December 31, 2025.

  • Revenue Plummets 43.1%

    Net sales for the year ended December 31, 2025, decreased by $2.18 million to $2.88 million, a 43.1% decline from the prior year, primarily due to product stock-outs and supply disruptions.

  • Net Losses Widen

    The company's net loss increased to $4.05 million in 2025 from $3.77 million in 2024, driven by lower revenue and continued fixed operating expenses.

  • Massive Post-Balance Sheet Dilution

    Between January 1, 2026, and May 26, 2026, the company issued 1.64 billion common shares, increasing total shares outstanding by over 385% to 2.07 billion. These issuances were entirely from convertible debt conversions, providing no cash proceeds to the company.


Analysis

Stemtech Corp's annual report reveals a company in severe financial distress. Revenue plummeted by 43.1% in 2025, and net losses widened. The company explicitly states substantial doubt about its ability to continue as a going concern, citing recurring losses, negative cash flows, and a significant working capital deficiency. Furthermore, the company is in default on certain debt agreements, and its internal controls over financial reporting are deemed ineffective due to multiple material weaknesses. Post-balance sheet, existing shareholders have faced massive dilution of over 385% from convertible debt conversions, with no cash proceeds received by the company. This filing paints a critical picture of operational and financial instability.

At the time of this filing, STEK was trading at $0.00 on OTC in the Trade & Services sector, with a market capitalization of approximately $46.4K. The 52-week trading range was $0.00 to $0.04. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STEK - Latest Insights

STEK
May 29, 2026, 5:05 PM EDT
Source: Wiseek News
Importance Score:
8
STEK
May 29, 2026, 4:58 PM EDT
Filing Type: 10-K
Importance Score:
9